Protara Therapeutics (TARA) Stock Price, News & Analysis

Company Overview

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.

Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications. The company’s development programs are centered on advancing novel therapies through clinical testing and, if successful, obtaining regulatory approval for use in appropriate patient populations.

The company was formed through the combination of ArTara Therapeutics and Protara Therapeutics and began trading under the Protara name in 2020. Protara is headquartered in New York and conducts its research and clinical development activities through collaborations and studies in the United States. Jesse Shefferman serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $2.33 to $2.51
• 50-Day Range: $2.13 to $3.97
• 52-Week Range: $2.09 to $7.82
• Volume: 460,625 shs
• Average Volume: 933,760 shs
• Market Capitalization: $149.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.25
• Consensus Rating: Moderate Buy

Protara Therapeutics Stock Analysis - MarketRank™

Protara Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 540th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Protara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Protara Therapeutics has a consensus price target of $26.25, representing about 980.2% upside from its current price of $2.43.

Amount of Analyst Coverage

Protara Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.40) to ($1.69) per share.

Price to Book Value per Share Ratio

Protara Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.93% of the float of Protara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protara Therapeutics has a short interest ratio ("days to cover") of 2.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Protara Therapeutics has recently decreased by 46.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protara Therapeutics does not currently pay a dividend.

Dividend Growth

Protara Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.87

News Sentiment

Protara Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Protara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.60% of the stock of Protara Therapeutics is held by insiders.

Percentage Held by Institutions

38.13% of the stock of Protara Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/06/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TARA
• Previous Symbol: NASDAQ:PRTO
• CIK: 1359931
• Web: www.protaratx.com
• Phone: (646) 844-0337
• Fax: 781-487-6729
• Employees: 51
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Protara Therapeutics: $26.25
• High Price Target: $28.00
• Low Price Target: $24.00
• Potential Upside/Downside: +980.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.15%
• Return on Assets: -42.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.01
• Quick Ratio: 10.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.29 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 61,570,000
• Free Float: 54,604,000
• Market Cap: $149.62 million
• Optionable: Optionable
• Beta: 1.54